Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of HK$31.78B. The enterprise value is HK$25.11B.
Market CapHK$31.78B
Enterprise ValueHK$25.11B
Share Statistics
Livzon Pharmaceutical Group has 299,807,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding299,807,130
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 10.85%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)10.85%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee1.28M
Profits Per Employee217.37K
Employee Count9,067
Asset Turnover0.48
Inventory Turnover2.67
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is 11.6. Livzon Pharmaceutical Group’s PEG ratio is -8.67.
PE Ratio11.6
PS Ratio1.97
PB Ratio1.65
Price to Fair Value1.65
Price to FCF9.02
Price to Operating Cash Flow9.66
PEG Ratio-8.67
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of 11.60B and earned 1.97B in profits. Earnings per share was 2.21.
Revenue11.60B
Gross Profit7.43B
Operating Income2.56B
Pretax Income2.79B
Net Income1.97B
EBITDA3.10B
Earnings Per Share (EPS)2.21
Cash Flow
In the last 12 months, operating cash flow was 3.19B and capital expenditures -579.19M, giving a free cash flow of 2.61B billion.
Operating Cash Flow3.19B
Free Cash Flow2.61B
Free Cash Flow per Share8.70
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of HK$1.199, resulting in a dividend yield of 4.09%
Dividend Per ShareHK$1.199
Dividend Yield4.09%
Payout Ratio46.11%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change18.40%
50-Day Moving Average28.65
200-Day Moving Average31.99
Relative Strength Index (RSI)61.48
Average Volume (3m)553.85K
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Apr 24, 2026, TBA (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateApr 24, 2026
Ex-Dividend Date―
Financial Position
Livzon Pharmaceutical Group as a current ratio of 2.23, with Debt / Equity ratio of 27.21%
Current Ratio2.23
Quick Ratio2.02
Debt to Market Cap0.17
Net Debt to EBITDA-1.76
Interest Coverage Ratio42.50
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid 439.34M in taxes.
Income Tax439.34M
Effective Tax Rate0.16
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is 5.63, with an EV/FCF ratio of 6.86.
EV to Sales1.50
EV to EBITDA5.63
EV to Free Cash Flow6.86
EV to Operating Cash Flow5.62
Balance Sheet
Livzon Pharmaceutical Group has HK$10.93B in cash and marketable securities with HK$3.85B in debt, giving a net cash position of HK$7.08B billion.
Cash & Marketable SecuritiesHK$10.93B
Total DebtHK$3.85B
Net CashHK$7.08B
Net Cash Per ShareHK$23.61
Tangible Book Value Per ShareHK$16.61
Margins
Gross margin is 65.45%, with operating margin of 22.03%, and net profit margin of 16.99%.
Gross Margin65.45%
Operating Margin22.03%
Pretax Margin24.03%
Net Profit Margin16.99%
EBITDA Margin26.68%
EBIT Margin22.03%
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is HK$22.99, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price TargetHK$22.99
Price Target Upside-25.69% Downside
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast-0.45%
EPS Growth Forecast9.00%